- Home
- CAPR vs CYRX Comparison
CAPR vs CYRX Comparison
Compare CAPR & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- CYRX
- Stock Information
- Founded
- CAPR 2005
- CYRX 1999
- Country
- CAPR United States
- CYRX United States
- Employees
- CAPR N/A
- CYRX N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- CYRX Biotechnology: Pharmaceutical Preparations
- Sector
- CAPR Health Care
- CYRX Health Care
- Exchange
- CAPR Nasdaq
- CYRX Nasdaq
- Market Cap
- CAPR 453.9M
- CYRX 365.5M
- IPO Year
- CAPR N/A
- CYRX N/A
- Fundamental
- Price
- CAPR $11.66
- CYRX $7.51
- Analyst Decision
- CAPR Strong Buy
- CYRX Strong Buy
- Analyst Count
- CAPR 8
- CYRX 9
- Target Price
- CAPR $33.75
- CYRX $10.67
- AVG Volume (30 Days)
- CAPR 3.0M
- CYRX 563.6K
- Earning Date
- CAPR 08-06-2025
- CYRX 08-05-2025
- Dividend Yield
- CAPR N/A
- CYRX N/A
- EPS Growth
- CAPR N/A
- CYRX N/A
- EPS
- CAPR N/A
- CYRX N/A
- Revenue
- CAPR $17,363,588.00
- CYRX $232,134,000.00
- Revenue This Year
- CAPR $258.96
- CYRX N/A
- Revenue Next Year
- CAPR $8.02
- CYRX $9.63
- P/E Ratio
- CAPR N/A
- CYRX N/A
- Revenue Growth
- CAPR N/A
- CYRX 11.75
- 52 Week Low
- CAPR $3.52
- CYRX $4.58
- 52 Week High
- CAPR $23.40
- CYRX $9.78
- Technical
- Relative Strength Index (RSI)
- CAPR 50.35
- CYRX 60.89
- Support Level
- CAPR $9.65
- CYRX $7.20
- Resistance Level
- CAPR $10.56
- CYRX $7.70
- Average True Range (ATR)
- CAPR 1.21
- CYRX 0.44
- MACD
- CAPR -0.02
- CYRX 0.03
- Stochastic Oscillator
- CAPR 70.08
- CYRX 80.97
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.